Targeting CD30 in anaplastic large cell lymphoma

Joseph Vadakara, Barbara Pro*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by strong and uniform expression of the CD30 antigen on the cell surface. Current standard frontline therapy of ALCL is anthracycline-based combination chemotherapy, usually CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOPlike regimens. Despite aggressive chemotherapy a significant number of patients relapse. Newer agents and strategies are needed in the management of this challenging disease especially in ALK-negative and high-risk ALK-positive patients who tend to have a poor prognosis. In this review we discuss the different approaches to targeting CD30 including naked antibodies, "enhanced antibodies", antibody drug-toxin conjugates, radioimmunoconjugates, CD30-ligand-toxin conjugates, bispecific antibodies and T cellbased immune therapies.

Original languageEnglish (US)
Pages (from-to)285-291
Number of pages7
JournalCurrent Hematologic Malignancy Reports
Volume7
Issue number4
DOIs
StatePublished - Dec 1 2012

Keywords

  • Anaplastic large cell lymphoma
  • Brentuximab
  • CD30
  • MMAE
  • SGN-35
  • T-cell lymphoma
  • Vedotin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting CD30 in anaplastic large cell lymphoma'. Together they form a unique fingerprint.

Cite this